Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Go back to Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study| (NYSE: UCB) | Delayed: 35.18 -0.05 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.23 | 52 Week High | $ | |||
| Open | $35.39 | 52 Week Low | $ | |||
| Day High | $35.60 | P/E | N/A | |||
| Day Low | $35.12 | EPS | $ | |||
| Volume | 682,005 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 125.29 -3.54 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.83 | 52 Week High | $46.25 | |||
| Open | $126.26 | 52 Week Low | $32.74 | |||
| Day High | $126.69 | P/E | N/A | |||
| Day Low | $125.00 | EPS | $0.00 | |||
| Volume | 20,642 | |||||
